ANI PHARMACEUTICALS, INC APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ANI PHARMACEUTICALS, INC (ANIP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $21.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2012 was $725.63K, a 38.39% decline from fiscal 2011.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2011 was $1.18M, a 18.63% increase from fiscal 2010.
- ANI PHARMACEUTICALS, INC apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2010 was $992.76K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|
| 2026-06-30 | $21.70M 10-Q · filed 2026-08-07 | |
| 2012-12-31 | $725.63K 10-K · filed 2013-02-28 | |
| 2011-12-31 | $1.18M 10-K · filed 2013-02-28 | |
| 2010-12-31 | $992.76K 10-K · filed 2013-02-28 | |
| 2009-12-31 | $1.25M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |